Immunic, inc. to participate in investor and scientific conferences in september

New york, sept. 8, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in september: september 13-15: h.c.
IMUX Ratings Summary
IMUX Quant Ranking